Drug-Induced Sarcoid-like Reactions: When Drugs Mimic Sarcoidosis in Respiratory Practice
Journal of Clinical Medicine · 2026-11-12 · 15 (22) · 8863
DOI: 10.3390/jcm15228863 ↗Abstract
Drug-induced sarcoid-like reactions (DISRs) are uncommon granulomatous disorders that develop in temporal association with drug exposure and closely resemble sarcoidosis clinically, radiologically, and histologically. Their recognition has become increasingly relevant with the expanding use of immune-modulating and targeted therapies. Immune checkpoint inhibitors and tumor necrosis factor-alpha inhibitors are among the best-documented causes, while sarcoid-like reactions have also been reported with interferons, dupilumab, BRAF/MEK inhibitors, and other biologic and targeted agents. Thoracic involvement is particularly common and typically manifests as bilateral hilar or mediastinal lymphadenopathy, with or without pulmonary parenchymal abnormalities. In patients with cancer, these findings may mimic disease progression and lead to inappropriate modification of effective anticancer therapy. Imaging findings are not specific, and histological confirmation may therefore be necessary when the differential diagnosis would alter clinical management. Management should be individualized according to clinical severity, organ involvement, diagnostic certainty, and the importance of continuing the suspected drug. Observation or continuation of therapy may be appropriate in selected asymptomatic or limited cases, whereas drug withdrawal and systemic corticosteroids may be required in symptomatic or multisystem disease. This narrative review summarizes current evidence on DISRs, with particular emphasis on pulmonary and intrathoracic manifestations, associated drug classes, diagnostic challenges, management, and outcomes. A respiratory-focused diagnostic pathway is proposed, integrating comparison with prior imaging, targeted microbiological sampling, selective bronchoscopic or other tissue biopsy, and assessment of competing diagnoses, including malignancy and immune checkpoint inhibitor pneumonitis. The pathway also supports individualized decisions on observation, drug continuation, or withdrawal; it is not a validated diagnostic instrument.
EUVIMED